Navigation Links
MEDRAD Introduces Manage.Report - Advances Evidence-Based Decision Making

New Informatics Solution enables healthcare professionals to more immediately identify, validate and respond to clinical and administrative information

WARRENDALE, Pa., June 3 /PRNewswire/ -- MEDRAD, Inc. has launched Manage.Report, an informatics application that enables healthcare professionals to immediately access clinical and administrative information associated with radiology patients' contrast injections from nearly anywhere. This is the first in the company's series of informatics platform applications, and radiology imaging's premier browser-based informatics solution.

(Logo: )

Manage.Report automatically captures and logs in a secure database essential patient and radiology-management information concerning contrast injections delivered by the MEDRAD Stellant(R) CT injector. In addition to meeting the needs of clinical teams through immediate access to patient-specific injection information, Manage.Report automates record keeping, increases data accuracy, simplifies the audit process and facilitates compliance with the Joint Commission. RIS/PACS integration and remote service extensions are under development for the informatics solution, a platform based on service-oriented architecture and flexible design.

"Whether focusing on improved patient care, consistency in outcomes or increasing productivity, Manage.Report removes barriers to accessing the information that evidence-based decision making demands," says Anthony Cinalli, executive director, Radiology Marketing. "Healthcare professionals can identify need and determine the course of action by analyzing robust clinical and administrative data sets they choose to monitor."

Manage.Report automatically captures procedure information in a secure database. Within moments after the scan, radiologists can log in and review details on the actual protocols administered to their patients and consider injection specifics associated with the procedure such as pressure rates and flow graphs. Administrators can track procedure volumes, contrast usage and injection events, and conduct detailed analysis using robust, customized reporting capabilities.

About MEDRAD, Inc.

MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care. More company information is available at

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

Cautionary statement regarding forward-looking statements.

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD(R) Revenues Grow 10 Percent in 2008
2. MEDRAD Multi Vendor Service Launches TotalRepair(SM) on Select Ultrasound Probes
3. MEDRAD Molecular Imaging Earns Top Rank in Innovation
4. MEDRAD Sponsors PET Research with University of Zurich
5. MEDRAD Builds on Success of P3T Cardiac CT Injection Software
6. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
7. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
8. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
9. MEDRAD(R) Revenues Grow 10 Percent in 2007
10. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
11. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology: